News Conference News ESC 2025 HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients Caitlin E. Cox September 01, 2025
News Conference News ACC 2025 Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT Caitlin E. Cox March 29, 2025
News Daily News New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients L.A. McKeown August 19, 2024
News Daily News DOAC Don’ts: New Review Clarifies When Not to Use Direct Oral Anticoagulants Shelley Wood January 17, 2024
News Conference News ESC 2023 ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients L.A. McKeown August 30, 2023
Presentation Fellows 2023 FLAME and clinical implications for high risk PE Presenter: Jay Giri May 12, 2023
Presentation Fellows 2023 A cardiologist’s perspective on the importance of treating VTE Presenter: Sahil Parikh May 12, 2023
Presentation Fellows 2023 The VTE landscape – where we are and where we’re going Presenter: Thomas Tu May 12, 2023
Presentation Fellows 2023 New Technology to Address VTE Thrombus Removal Presenter: S. Jay Mathews May 11, 2023
News Daily News Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest Michael O'Riordan October 20, 2022
Presentation TCT 2022 Catheter-Based Management of Infectious Endocarditis Presenter: Abdallah El Sabbagh September 19, 2022
Presentation TCT 2022 Introduction to the PE/VTE landscape and critical unmet needs Presenter: Shon Chakrabarti September 19, 2022
Presentation TCT 2022 Case 3: Post-Partum May-Thurner Acute DVT Presenter: Maya Serhal September 18, 2022